Agilent delivered another decent quarter with robust growth across all geographies and end-markets. The company witnessed a strong momentum across each of its segments i.e., Life Sciences & Applied Markets Group, Agilent Cross Lab Group, and Diagnostics and Genomics Group. Pharma as an industry has performed well over the past few quarters and there has been a strong demand for the company’s offerings in cell analysis, liquid chromatography and mass spectrometry. The Chinese market in particular, has been a strong contributor to Agilent’s growth in the recent quarter. The company’s top-line has also been driven by growth in the consumption of its cancer diagnostic offerings, genomics instrumentation and consumables. We maintain our ‘Outperform’ rating on the stock with a revised target price.
Our Report Structure:
⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
Want unlimited access to our reports? Purchase our $496 annual subscription!